Haluk Alibazoglu
Haluk Alibazoglu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Adam M Khalil
Medical School, Weill Cornell Medicine, Doha, Qatar
1 shared publicationAhmed Bafadel
Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE
1 shared publicationAhmed Sherif
Imaging Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE
1 shared publicationAmany Hillis
Dept. of Cardiology, SEHA, Abu Dhabi, UAE
1 shared publicationAndrew L. Rivard
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
1 shared publicationBuket Alibazoglu
Dept. of Cardiology, CardioCheck, Ankara, Turkey
1 shared publication
Latest Publications
- Open Access
- 22 May 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (8) , 3970-3976
Unraveling septal perfusion abnormalities in Ebstein's anomaly: A case report contrasting PET MPI with myocardial reality
- 22 May 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (8) , 3970-3976
Open AccessUnraveling septal perfusion abnormalities in Ebstein's anomaly: A case report contrasting PET MPI with myocardial reality
- Open Access
- 1 March 2023
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 30 (5) , 1922-1934
Attacking the Achilles heel of cardiac amyloid nuclear scintigraphy: How to reduce equivocal and false positive studies
- 1 March 2023
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 30 (5) , 1922-1934
Open AccessAttacking the Achilles heel of cardiac amyloid nuclear scintigraphy: How to reduce equivocal and false positive studies
- 28 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , S23-S24
Characteristics And Outcomes Of Patients Evaluated At A Newly Established Cardiac Amyloidosis Program: Insight From The Middle East/ Gulf Region
- 28 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , S23-S24
Characteristics And Outcomes Of Patients Evaluated At A Newly Established Cardiac Amyloidosis Program: Insight From The Middle East/ Gulf Region
- Open Access
- 25 June 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8, 644508
From Clinical Clues to Final Diagnosis: The Return of Detective Work to Clinical Medicine in Cardiac Amyloidosis
Cardiac amyloidosis is frequently misdiagnosed, denying patients the opportunity for timely and appropriate management of the disease. The purpose of this review and case studies is to raise awareness of the diagnostic “red flags” associated with cardiac amyloidosis and the currently available non-invasive strategies for diagnosis. The review focuses on the identification of one of the two main types of cardiac amyloidosis, transthyretin amyloid cardiomyopathy, and non-invasive tools to distinguish this from light-chain amyloidosis. A diagnostic algorithm centered around the use of non-invasive imaging and laboratory analysis is presented. The algorithm generates four differential diagnoses for patients presenting with signs and symptoms consistent with cardiac amyloidosis. Case examples are presented, representing the four potential outcomes of diagnosis using the algorithm. The review provides a guide on how to recognize the often-overlooked presentations of this disease in clinical practice. Non-invasive imaging techniques and diagnostic tools that do not require the involvement of a specialty center have allowed for the improved diagnosis of cardiac amyloidosis. Timely diagnosis of this life-threatening disease is essential for optimal management and it is imperative that clinicians have a high index of suspicion for patients presenting with “red flag” symptoms.
- 25 June 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8, 644508
Open AccessFrom Clinical Clues to Final Diagnosis: The Return of Detective Work to Clinical Medicine in Cardiac Amyloidosis
Cardiac amyloidosis is frequently misdiagnosed, denying patients the opportunity for timely and appropriate management of the disease. The purpose of this review and case studies is to raise awareness of the diagnostic “red flags” associated with cardiac amyloidosis and the currently available non-invasive strategies for diagnosis. The review focuses on the identification of one of the two main types of cardiac amyloidosis, transthyretin amyloid cardiomyopathy, and non-invasive tools to distinguish this from light-chain amyloidosis. A diagnostic algorithm centered around the use of non-invasive imaging and laboratory analysis is presented. The algorithm generates four differential diagnoses for patients presenting with signs and symptoms consistent with cardiac amyloidosis. Case examples are presented, representing the four potential outcomes of diagnosis using the algorithm. The review provides a guide on how to recognize the often-overlooked presentations of this disease in clinical practice. Non-invasive imaging techniques and diagnostic tools that do not require the involvement of a specialty center have allowed for the improved diagnosis of cardiac amyloidosis. Timely diagnosis of this life-threatening disease is essential for optimal management and it is imperative that clinicians have a high index of suspicion for patients presenting with “red flag” symptoms.